Proposed Mechanisms Preclinical models, including several published in peer-reviewed journals, suggest BPC-157 acts through nitric oxide (NO) modulation, upregulation of growth hormone receptor expression, and interaction with dopaminergic and serotonergic pathways
OSI-906 (linsitinib), a RTKI targeting both IGF-1R and IR, was investigated as a treatment for hormone sensitive breast cancer in combination with endocrine therapy and erlonitib in a phase II clinical trial (NCT01205685)
Detox Water for Skin 7
Both share stomach-heavy side effects: nausea, vomiting, diarrhea, constipation, injection-site reactions
(PubMed) Lin PT, Cheng CH, Liaw YP, Lee BJ, Lee TW, Huang YC
Key benefits include: Sustained energy : Many patients notice improved stamina and reduced fatigue